-transparent.png){kind=logo}
OBJECTIVE Patients treated for Hodgkin disease (HD) are at increased risk for developing secondary neoplasms, including non-Hodgkin lymphoma (NHL). We present a patient who developed NHL (brain and lungs) as a second malignancy together with recurrent HD (bone marrow). Because HD and NHL have both been associated with Epstein-Barr virus (EBV), especially in the immunodeficient host, the tumor specimens were studied for the presence of EBV, and the possible role of immunodeficiency in the development of this second malignancy was assessed. RESULTS Tumor specimens were analyzed by conventional histologic and immunohistochemical methods, EBV detection was determined by RNA in situ hybridization for EBV- encoded RNAs (EBERs). Histopathology showed diffuse large cell lymphoma of B-cell phenotype in specimens from lesions in the brain and lungs. These specimens were EBER+. HD specimens from all recurrences were evaluated and were EBER. CONCLUSIONS This patient had received extensive chemoradiotherapy for recurrent HD, and presented with Pneumocystis pneumonia, a low absolute T-cell count, no response to mitogens in vitro, a second malignancy (EBV+NHL), and recurrent EBV-HD. We propose that the immunocompromised state of the patient played a significant role in the development of his second malignancy.
T G Gross, and
J M Hilden, and
J C Manivel, and
N K Ramsay, and
E M MacMahon
May 2018,
Cancers,
T G Gross, and
J M Hilden, and
J C Manivel, and
N K Ramsay, and
E M MacMahon
January 2007,
Hematology. American Society of Hematology. Education Program,
T G Gross, and
J M Hilden, and
J C Manivel, and
N K Ramsay, and
E M MacMahon
December 1991,
Blood,
T G Gross, and
J M Hilden, and
J C Manivel, and
N K Ramsay, and
E M MacMahon
December 1988,
Annals of internal medicine,
T G Gross, and
J M Hilden, and
J C Manivel, and
N K Ramsay, and
E M MacMahon
June 2005,
Journal of clinical pathology,
T G Gross, and
J M Hilden, and
J C Manivel, and
N K Ramsay, and
E M MacMahon
June 2014,
Hematology/oncology and stem cell therapy,
T G Gross, and
J M Hilden, and
J C Manivel, and
N K Ramsay, and
E M MacMahon
March 2004,
Southern medical journal,
T G Gross, and
J M Hilden, and
J C Manivel, and
N K Ramsay, and
E M MacMahon
January 2021,
SAGE open medicine,
T G Gross, and
J M Hilden, and
J C Manivel, and
N K Ramsay, and
E M MacMahon
August 2013,
Journal of neurosurgery,
T G Gross, and
J M Hilden, and
J C Manivel, and
N K Ramsay, and
E M MacMahon
November 2022,
The Journal of dermatology,
